Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: ROIV stock price vs ADSK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ADSK's multiple
Needs ADSK P/S.
Implied fair value · at ROIV's multiple
Needs ROIV P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · ADSK FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ROIVANT SCIENCES LTD. · implied price per share
Bear
$4.51
Base
$5.30
Bull
$6.10
AUTODESK, INC. · implied price per share
Bear
$58.20
Base
$68.47
Bull
$78.74
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.10x
0.92x
Net debt / EBITDA
Leverage against operating earnings
32.78x
0.11x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$2.60B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
JOHN WILEY & SONS, INC.
ROIV vs WLY
TRIMBLE INC.
ROIV vs TRMB
NVIDIA CORP
ROIV vs NVDA
ADOBE INC.
ROIV vs ADBE
ANSYS INC
ROIV vs ANSS
TYLER TECHNOLOGIES INC
ROIV vs TYL
$442.59M
$2.80B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ROIV can rapidly restore revenue growth and materially improve margins from deeply negative levels, then the current stock may be defensible; otherwise, the data support avoiding or underweighting ROIV because its valuation is far above ADSK despite much weaker fundamentals and quality.
ROIV trades at an extreme valuation premium versus ADSK on both earnings and sales-based measures, yet the implied P/S price of $0.07 is far below the current price of $35.15. The gap is driven by ROIV's much weaker revenue base and deeply negative profitability relative to ADSK's large, profitable, and growing business.
Supporting Metrics
